ORPHA:251287
Benign concentric annular macular dystrophy
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
49
39.6th percentile
Trials
0
Interventional, condition-specific
Researchers
310
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0007934
- MeSH:C537833
- OMIM:153870
- UMLS:C5561925
Additional Mondo synonyms (1)
retinitis pigmentosa 91
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
49 matched papers (27 in last 10 years) Source
- Phenotype characterisedPresent
3 HPO annotations (e.g. Macular dystrophy; Foveal hyperpigmentation; Dyschromatopsia) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
3
Associated phenotypes · MONDO:0007934
- Macular dystrophy
- Foveal hyperpigmentation
- Dyschromatopsia
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
49
49 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
49 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
27 in the last 10 years · high confidence · 39.6th percentile (publications denominator)
Phrase hits: 49 · MeSH hits: 0
Who's working on it?
310
Distinct author names in 49 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Cremers FP4 papers · 2017
Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
Papers in Europe PMC - 02Hoyng CB4 papers · 2021
Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
Papers in Europe PMC - 03Banfi S3 papers · 2021
Department of Precision Medicine, University of Campania "Luigi Vanvitelli", Telethon Institute of Genetics and Medicine, Naples, Italy.
Papers in Europe PMC - 04Deutman AF3 papers · 2004Papers in Europe PMC
- 05Dhaenens CM3 papers · 2026
University Lille-Nord de France, INSERM U837, Lille, France.
Papers in Europe PMC - 06Avila-Fernández A2 papers · 2021
Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)-Center for Biomedical Network Research on Rare Diseases-(CIBERER), Madrid, Spain.
Papers in Europe PMC - 07Bocquet B2 papers · 2021
Institute for Neurosciences of Montpellier, University of Montpellier, Montpellier, France.
Papers in Europe PMC - 08Corton M2 papers · 2021
Department of Genetics & Genomics, Instituto de Investigación Sanitaria-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)-Center for Biomedical Network Research on Rare Diseases-(CIBERER), Madrid, Spain.
Papers in Europe PMC - 09den Hollander AI2 papers · 2018
Department of Ophthalmology, Donders Institute for Brain, Cognition and Behaviour, Radboud University Medical Center, Nijmegen, the Netherlands.
Papers in Europe PMC - 10Ghosh A2 papers · 2020
Consultant VR Surgeon, Narayana Nethralaya Eye Institute, Bangalore, Karnataka, India.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 4 · after dedupe 4 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 4 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (4)
- isrctn·ISRCTN26775973·No longer recruiting·A study to assess the amount of active ingredient that reaches the blood circulation after administration of a new drug dissolvable in the mouth for treating the erectile dysfunction in comparison to the marketed tablet Cialis®, taken by healthy men under fed and fasting conditions
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN15394603·No longer recruiting·A study to assess the amount of sildenafil that reaches the blood circulation after administration of an oral film dissolvable in the mouth for treating erectile dysfunction in comparison to the marketed tablet Viagra®, both taken by healthy men under fed conditions
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN10466893·No longer recruiting·Study on the effect of three single ascending doses of sildenafil citrate oral film compared with placebo on blood pressure in healthy young and elderly males
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN52182476·No longer recruiting·Pharmacokinetics of a novel sildenafil orodispersible film administered by the supralingual and the sublingual route to healthy men
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Benign concentric annular macular dystrophy — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Benign concentric annular macular dystrophy" OR "retinitis pigmentosa 91"
MeSH descriptor terms unioned into the query: Macular dystrophy, concentric annular
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Benign concentric annular macular dystrophy" OR "retinitis pigmentosa 91" OR "Macular dystrophy, concentric annular"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T10:43:44.414Z